Evidence map›Paper›PMID 36327426›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.

Melissa L Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Konstantin Laktionov, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim and 10 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 284 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
284citing papers in PubMed, 17 pooled it
40.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

284 citing papers in PubMed, 17 syntheses or guidelines pooled it, 414 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

224 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 12 countries.

Melissa L JohnsonSarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN.ORCID 0000-0001-9874-1314
Byoung Chul ChoYonsei Cancer Center, Seoul, South Korea.ORCID 0000-0002-5562-270X
Alexander LuftLeningrad Regional Clinical Hospital, St Petersburg, Russia.
Jorge Alatorre-AlexanderHealth Pharma Professional Research, Mexico City, Mexico.
Sarayut Lucien GeaterPrince of Songkla University, Songkhla, Thailand.
Konstantin LaktionovFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia.ORCID 0000-0003-4469-502X
Sang-We KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Grygorii UrsolAcinus, Kropyvnytskyi, Ukraine.
Maen HusseinFlorida Cancer Specialists-Sarah Cannon Research Institute, Leesburg, FL.
Farah Louise LimQueen Mary University of London, London, United Kingdom.
Cheng-Ta YangChang Gung Memorial Hospital, Taoyuan City, Taiwan.
Luiz Henrique AraujoInstituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.ORCID 0000-0001-9486-7139
Haruhiro SaitoKanagawa Cancer Center, Yokohama, Japan.ORCID 0000-0002-8541-8339
Niels ReinmuthAsklepios Lung Clinic, member of the German Center for Lung Research (DZL), Munich-Gauting, Germany.
Xiaojin ShiAstraZeneca, Gaithersburg, MD.
Lynne PooleAstraZeneca, Cambridge, United Kingdom.
Solange PetersCentre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.ORCID 0000-0002-0412-7143
Edward B GaronDavid Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0001-7077-8801
Tony MokState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-8251-0551
POSEIDON investigators
Sarah Cannon · USAstraZeneca (Japan) · JPAstraZeneca (United Kingdom) · GBChinese University of Hong Kong · HKGerman Center for Lung Research · DEInstituto Nacional de Câncer - INCA · BRKanagawa Prefectural Hospital Organization · JPLeningrad Regional Cancer Center · RUMinistry of Health · ESPrince of Songkla University · THQueen Mary University of London · GBTaoyuan Chang Gung Memorial Hospital · TWUlsan College · KRUniversity Hospital of Lausanne · CHUniversity of California, Los Angeles · USYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC).

methodsPatients (n = 1,013) with

resultsPFS was significantly improved with D + CT versus CT (hazard ratio [HR], 0.74; 95% CI, 0.62 to 0.89;

conclusionD + CT significantly improved PFS versus CT. A limited course of tremelimumab added to durvalumab and chemotherapy significantly improved OS and PFS versus CT, without meaningful additional tolerability burden, representing a potential new option in first-line mNSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, MonoclonalAntibodies, Monoclonal, Humanizeddurvalumabtremelimumab

Identifiers

PMID36327426
PMCPMC9937097
OpenAlexW4308179948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.